The PD-1 blocking immunotherapy is the first approved treatment in a subset of rectal cancer patients, building on one ...
EMA supports dropping the prescription requirement for Mundipharma’s Nyxoid, but each EU state will decide where it is sold.
Amneal Defends Parkinson’s Franchise: Crexont Case Dropped By Sandoz, Rytary Antitrust Suit Advances
A Sandoz patent challenge to Amneal’s Crexont has been voluntarily dismissed without prejudice, but an Alembic suit heads to ...
The UK wants to change the way medtech companies interact with its medical regulator via a more transparent process and ...
Unlike a recent AI deal last week focused on drug discovery, AstraZeneca’s non-binding agreement with Oracle targets clinical trials, including patient recruitment.
As the FDA moves to speed early-stage clinical trials, former commissioners split on whether the public will see a reform or ...
Third positive data readout for the extended-release minoxidil positions drug for filing in male pattern hair loss, with ...
Office of Dietary Supplement Programs announces availability of “New Dietary Ingredient (NDI) Notifications and Related ...
AdvaMed CEO Scott Whitaker listed tariffs, user fees, reimbursement predictability and strengthening cybersecurity as his top ...
Dr. Squatch’s proposed $9m settlement over ‘natural’ claims and Sol de Janeiro’s trade dress dispute with MCoBeauty offer two ...
Chief global commercialization officer Anthony Mancini talked to Scrip about why the company is building a commercial ...
The European Commission tells the Pink Sheet that Aumseqa’s unprecedented EU revocation was purely a regulatory ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results